Literature DB >> 23564379

CCL2/CCR2 augments the production of transforming growth factor-beta1, type 1 collagen and CCL2 by human CD45-/collagen 1-positive cells under high glucose concentrations.

Akinori Hara1, Norihiko Sakai, Kengo Furuichi, Yoshio Sakai, Motohiro Takeya, Richard Bucala, Naofumi Mukaida, Yoh Takuwa, Kouji Matsushima, Shuichi Kaneko, Takashi Wada.   

Abstract

BACKGROUND: The migration and activation of circulating profibrotic cells including fibrocytes by the action of the chemokine/chemokine receptor system has been implicated in pathological fibrogenesis. In the present study, the involvement of collagen 1 (Col1)-producing cells, CD45-positive/collagen-1-positive (CD45(+)/Col1(+)) cells originally named as fibrocytes via CC chemokine receptor 2 (CCR2), a cognate receptor of CCL2/monocyte chemoattractant protein, was examined in diabetic conditions.
METHODS: Human CD45(+)/Col1(+) cells originating from the peripheral blood of healthy volunteers were incubated with high concentrations of D-glucose or D-mannitol as an osmotic control for 12, 24 or 48 h. In addition, these cells were preincubated with CCL2 under high glucose concentrations. We also examined the effects of the inhibitors of glucose transporters (GLUTs), reactive oxygen species or CCR2 on the expression of transforming growth factor beta1 (TGF-β1), pro-α1 chain of Col1 (COL1A1), and CCL2.
RESULTS: Stimulation of CD45(+)/Col1(+) cells with high glucose concentrations increased the mRNA and protein levels of TGF-β1 and CCL2 and those of pro-COL1A1, and this effect was mediated in part by increased osmolality. Preincubation of the cells with cytochalasin B (a GLUT inhibitor) or N-acetylcysteine (an antioxidant) blocked the stimulatory effect of high glucose concentrations on these profibrotic molecules. In addition, preincubation of the cells with CCL2 enhanced the high glucose-induced upregulation of TGF-β1, pro-COL1A1 and CCL2 and migration of the cells, and this effect was partly inhibited by treatment with CCR2 inhibitors.
CONCLUSION: These results suggest that CD45(+)/Col1(+) cells may be directly involved, in part through CCL2/CCR2 signaling, in the fibrotic process under diabetic conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23564379     DOI: 10.1007/s10157-013-0796-6

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  38 in total

1.  MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes.

Authors:  Norihiko Sakai; Takashi Wada; Kengo Furuichi; Kazuaki Shimizu; Satoshi Kokubo; Akinori Hara; Junya Yamahana; Toshiya Okumura; Kouji Matsushima; Hitoshi Yokoyama; Shuichi Kaneko
Journal:  J Leukoc Biol       Date:  2006-01-13       Impact factor: 4.962

Review 2.  Osmosensory mechanisms in cellular and systemic volume regulation.

Authors:  Stine Falsig Pedersen; András Kapus; Else K Hoffmann
Journal:  J Am Soc Nephrol       Date:  2011-08-18       Impact factor: 10.121

3.  Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis.

Authors:  Norihiko Sakai; Takashi Wada; Hitoshi Yokoyama; Martin Lipp; Satoshi Ueha; Kouji Matsushima; Shuichi Kaneko
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

Review 4.  Fibrocytes: a new insight into kidney fibrosis.

Authors:  T Wada; N Sakai; K Matsushima; S Kaneko
Journal:  Kidney Int       Date:  2007-05-09       Impact factor: 10.612

5.  Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis.

Authors:  Roderick J Phillips; Marie D Burdick; Kurt Hong; Marin A Lutz; Lynne A Murray; Ying Ying Xue; John A Belperio; Michael P Keane; Robert M Strieter
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 6.  Glucose metabolism in lymphoid and inflammatory cells and tissues.

Authors:  Philip C Calder; George Dimitriadis; Philip Newsholme
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2007-07       Impact factor: 4.294

7.  Role of CC chemokine receptor 2 in bone marrow cells in the recruitment of macrophages into obese adipose tissue.

Authors:  Ayaka Ito; Takayoshi Suganami; Akira Yamauchi; Mikako Degawa-Yamauchi; Miyako Tanaka; Ryuji Kouyama; Yuko Kobayashi; Nao Nitta; Kazuki Yasuda; Yukio Hirata; William A Kuziel; Motohiro Takeya; Shiro Kanegasaki; Yasutomi Kamei; Yoshihiro Ogawa
Journal:  J Biol Chem       Date:  2008-10-30       Impact factor: 5.157

8.  Fibrocytes are involved in the pathogenesis of human chronic kidney disease.

Authors:  Norihiko Sakai; Kengo Furuichi; Yasuyuki Shinozaki; Hiroyuki Yamauchi; Tadashi Toyama; Shinji Kitajima; Toshiya Okumura; Satoshi Kokubo; Motoo Kobayashi; Kazuya Takasawa; Shin-ichi Takeda; Mitsuhiro Yoshimura; Shuichi Kaneko; Takashi Wada
Journal:  Hum Pathol       Date:  2009-12-29       Impact factor: 3.466

9.  Blockade of CCR2 ameliorates progressive fibrosis in kidney.

Authors:  Kiyoki Kitagawa; Takashi Wada; Kengo Furuichi; Hiroyuki Hashimoto; Yoshiro Ishiwata; Masahide Asano; Motohiro Takeya; William A Kuziel; Kouji Matsushima; Naofumi Mukaida; Hitoshi Yokoyama
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

10.  Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes.

Authors:  Elena Tarabra; Sara Giunti; Federica Barutta; Gennaro Salvidio; Davina Burt; Giacomo Deferrari; Roberto Gambino; Daniela Vergola; Silvia Pinach; Paolo Cavallo Perin; Giovanni Camussi; Gabriella Gruden
Journal:  Diabetes       Date:  2009-07-08       Impact factor: 9.461

View more
  2 in total

Review 1.  The emerging role of fibrocytes in ocular disorders.

Authors:  Feng Zhang; Ke Liu; Han Zhao; Yan He
Journal:  Stem Cell Res Ther       Date:  2018-04-13       Impact factor: 6.832

Review 2.  Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents.

Authors:  Kanae Yumimoto; Shigeaki Sugiyama; Koshi Mimori; Keiichi I Nakayama
Journal:  Cancer Sci       Date:  2019-06-10       Impact factor: 6.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.